




**Figure S1.** Body weight and body weight gain in controls and mice on an SD treated with doxepin (5 mg/kg/day) over 56 treatment days.




**Figure S2.** *UCP1* mRNA expression in the brown adipose tissue of control and doxepin-treated obese mice over 56 treatment days.




**Figure S3.** Serum-soluble leptin receptor levels of controls and doxepin-treated obese mice over 56 treatment days.




**Figure S4.** Serum serotonin levels of controls and doxepin-treated obese mice over 56 treatment days.




**Figure S5.** Serum FGF-21 levels of controls and doxepin-treated obese mice over 56 treatment days.




**Figure S6.** (a) Islet morphology (H&E staining and IHC) and (b)  $\beta$ -cell percentage of controls and doxepin-treated obese mice over 56 treatment days (magnification, 200 $\times$ ).




**Figure S7.** Serum (a) CRP, (b) IL-1 $\beta$ , and (c) TNF- $\alpha$  levels in controls and doxepin-treated obese mice over 56 treatment days.



**Figure S8.** (a) IHC and (b) expression of F4/80 in the livers of controls and doxepin-treated obese mice over 56 treatment days (magnification, 200×).



**Figure S9.** (a) IHC for and (b) expression of IL-1 $\beta$  in the kidneys of controls and doxepin-treated obese mice over 56 treatment days (magnification, 200 $\times$ ).



**Figure S10.** Body weight and weekly body weight gain in controls and mice receiving doxepin treatment (2 mg/kg/day) over 56 treatment days.